BOSTON, May 13, 2020 /PRNewswire/ -- Proteostasis
Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical
company dedicated to the discovery and development of
groundbreaking therapies to treat cystic fibrosis (CF), today
announced that Proteostasis management will present at the 2020 RBC
Capital Markets Global Healthcare Virtual Conference on
Wednesday, May 20, 2020 at
1:55 p.m. ET.
A live audio webcast of the RBC fireside chat will be available
on the Investor Events page in the Investors & Media section of
the Company's website, www.proteostasis.com. A replay of the
webcast will be available on the Company's website following the
presentation.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage
biopharmaceutical company developing small molecule therapeutics to
treat cystic fibrosis and other diseases caused by dysfunctional
protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team
focuses on identifying therapies that restore protein function. For
more information, visit www.proteostasis.com.
Safe Harbor
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the expected
presentation at an upcoming conference. Words such as "aim," "may,"
"will," "expect," "anticipate," "estimate," "intend," and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied by the forward-looking
statements, and we, therefore cannot assure you that our plans,
intentions, expectations or strategies will be attained or
achieved. Such risks and uncertainties include, without
limitation, the potential of our proprietary combination therapies
for the treatment of CF, the potential benefit of our proprietary
combination therapies to patients, expected completion of our
clinical studies and cohorts for our clinical programs, initiation
of a pivotal or registrational study, the possibility final or
future results from our drug candidate trials (including, without
limitation, longer duration studies) do not achieve positive
results or are materially and negatively different from or not
indicative of the preliminary results reported by us (noting that
these results are based on a small number of patients and small
data set), uncertainties inherent in the execution and completion
of clinical trials (including, without limitation, the possibility
that FDA or other regulatory agency comments delay, change or do
not permit trial commencement, or intended label, or the FDA or
other regulatory agency requires us to run cohorts sequentially or
conduct additional cohorts or pre-clinical or clinical studies), in
the enrollment of CF patients in our clinical trials in a
competitive clinical environment, in the timing of availability of
trial data, in the results of the clinical trials, in possible
adverse events from our trials, in the actions of regulatory
agencies, in the endorsement, if any, by therapeutic development
arms of CF patient advocacy groups (and the maintenance thereof).
In addition, the COVID-19 pandemic and the associated containment
efforts have had a serious adverse impact on the economy, the
severity and duration of which are uncertain. The pandemic could
have a material adverse impact on our business, operations and
financial results for an extended period of time. For a discussion
of other risks and uncertainties, and other important factors, any
of which could cause our actual results to differ from those
contained in the forward-looking statements, see the section
entitled "Risk Factors" in our most recent Annual Report on Form
10-K, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the
Securities and Exchange Commission. We assume no obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, unless
required by law.
CONTACTS:
Investors:
David Pitts
/ Claudia Styslinger
Argot Partners
212.600.1902
david@argotpartners.com / claudia@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-to-present-at-the-2020-rbc-capital-markets-global-healthcare-virtual-conference-301058479.html
SOURCE Proteostasis Therapeutics, Inc.
